# Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients

> **NCT02763644** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 7 (actual)

## Conditions studied

- Transplant Associated Microangiopathy TAM

## Interventions

- **DRUG:** LFG316 active drug
- **OTHER:** Standard of care treatment

## Key facts

- **NCT ID:** NCT02763644
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-22
- **Primary completion:** 2017-02-10
- **Final completion:** 2017-06-30
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** LFG316, had been studied in seven patients with transplantation-associated microangiopathy. Due to low confidence of clinical benefit, this study was closed.
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02763644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02763644, "Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02763644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*